EMA Recommends Approval of Three Biosimilars
The agency recommended nine drugs including treatments for diabetes, hepatitis B, and HIV.
The European Medicines Agency (EMA) announced during its November 2016 meeting that the agency’s Committee for Medicinal Products for Human Use (CHMP) was recommending nine drugs for approval. Three of the approved drugs were biosimilars: Lusduna (insulin glargine) for the treatment of diabetes, and Movymia and Terrosa (both containing teriparatide) for the treatment of osteoporosis. Generics Darunavir Mylan (darunavir), for the treatment of HIV-1, and Tadalafil Generics (tadalafil), for the treatment of pulmonary arterial hypertension were also approved.
Marketing authorization approval was also given to Afstyla (lonoctocog alfa) for the prevention and treatment of bleeding in patients with haemophilia A; Vemlidy (tenofovir alafenamide) for the treatment of chronic hepatitis B; Fiasp (insulin aspart) for the treatment of diabetes; and Suliqua (insulin glargine/lixisenatide) for the treatment of type 2 diabetes.
Conditional marketing authorization was renewed for Translarna, a treatment for Duchenne muscular dystrophy. CHMP also recommended therapeutic indication extension for Arzerra, Caprelsa, Humira, Nimenrix, and Vimpat.
Source: EMA
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
